AKT1 and cervical carcinoma: In summary, hsa‐mir‐133a‐2 could inhibit the pathway of PI3K/AKT by targeting LAMB3 in cervical cancer, thereby inhibiting cervical cancer cell proliferation and invasion (Figure 7).